CSL Limited, a prominent health care biotechnology company headquartered in Parkville, Australia, continues to maintain its significant presence in the biotechnology sector. As of March 26, 2026, the company is listed on the ASX All Markets stock exchange, with its shares trading at a close price of AUD 144.35 on March 25, 2026. This price reflects a notable fluctuation over the past year, with a 52-week high of AUD 275.79 recorded on July 29, 2025, and a 52-week low of AUD 133.35 on March 18, 2026. The company’s market capitalization stands at AUD 44.16 billion, underscoring its substantial influence within the industry.
CSL Limited specializes in the development, manufacturing, and marketing of human pharmaceutical and diagnostic products derived from human plasma. The company’s diverse product portfolio includes pediatric and adult vaccines, infection and pain medicines, skin disorder remedies, antivenoms, anticoagulants, and immunoglobulins. This extensive range of products highlights CSL’s commitment to addressing a wide array of health care needs.
On March 26, 2026, State Street Global Advisors released its daily fund update for the SPDR S&P/ASX 50 ETF, which includes CSL Ltd. as one of its constituent stocks. The report provided detailed information on the net asset value and cash component figures for the creation unit, although no trading activity or changes in units on issue were reported. The update also contained standard disclosures regarding the ETF’s structure and regulatory information, ensuring transparency and compliance with relevant financial regulations.
CSL Limited’s robust market position and comprehensive product offerings continue to solidify its role as a key player in the global biotechnology landscape. For further information on their products and services, interested parties can visit CSL’s official website at www.csl.com.au .
